Guided Therapeutics Q2 net loss narrows 29.44% to $604,000; revenue drops to no revenue - GTHP News | RalliesGuided Therapeutics Q2 net loss narrows 29.44% to $604,000; revenue drops to no revenue
G
GTHP• Second-quarter results narrow loss but revenue falls to zero
- Guided Therapeutics posted a net loss attributable to common stockholders of $604,000 in Q2 2026, narrowing from $856,000 a year earlier.
- Revenue was nil, versus $117,000 a year earlier; deferred revenue totaled $189,000 on advance customer payments.
- R&D expense fell 74.4% to $34,000 on lower clinical research costs after completing FDA-related clinical trials.
- General and administrative expense dropped 35.7% to $423,000, partly due to the prior-year warrant compensation charge for Dr. Mark Faupel.
- FDA clinical results were filed in June 2026; China NMPA inspection is targeted for Q3 2026, with approval possible in Q4 2026 or Q1 2027.
